EMA finding a possible link between the Janssen COVID-19 vaccine and very rare cases of unusual blood clots with low blood platelets
EMA finding a possible link between the Janssen COVID-19 vaccine and very rare cases of unusual blood clots with low blood platelets
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
The European Medicines Agency (EMA) has published a press release stating it finds a possible link between the Janssen COVID-19 vaccine and very rare cases of unusual blood clots with low blood platelets, but confirms that overall benefit-risk remains positive.
The European Medicines Agency (EMA) has published a press release stating it finds a possible link between the Janssen COVID-19 vaccine and very rare cases of unusual blood clots with low blood platelets, but confirms that overall benefit-risk remains positive.
Publication
What our experts say
Context and background
Resources
Expert Comments:
Prof Jonathan Ball
These side effects are very similar to those reported for Astra Zeneca COVID-19 vaccines, which does suggest that it is the inactivated Adenovirus delivery system that might be causing the problems. It’s important to remember though, that in most people the benefits of these vaccines far outweigh the risks – these are incredibly rare potential side-effects.
